Sionna Therapeutics (SION) Return on Capital Employed (2025 - 2026)
Quarterly results put Return on Capital Employed at 32.36% for Q1 2026, down 362.0% from a year ago — trailing twelve months through Mar 2026 was 32.36% (down 362.0% YoY), and the annual figure for FY2025 was 36.45%, changed.
Sionna Therapeutics has reported Return on Capital Employed over the past 2 years, most recently at 32.36% for Q1 2026.
- Return on Capital Employed reached 32.36% in Q1 2026 per SION's latest filing, down from 27.73% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.82% in Q2 2025 and bottomed at 32.36% in Q1 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 21.10% |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 10.19% |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 20.34% |
| 10 | Sionna Therapeutics | 1.87 Bn | 1.87 Bn | - | -32.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.36% |
| Dec 31, 2025 | -27.73% |
| Sep 30, 2025 | -24.87% |
| Jun 30, 2025 | -24.82% |
| Mar 31, 2025 | -28.74% |